Monoamine neurotransmitter deficiencies

Area of Science:

• Neurology
• Metabolic Disorders
• Genetics

Background:

• Pediatric neurotransmitter disorders are inherited neurometabolic syndromes.
• These conditions stem from disruptions in neurotransmitter synthesis, degradation, or transport.
• Monoamine deficiencies are a key category, impacting dopamine, serotonin, norepinephrine, and epinephrine.

Purpose of the Study:

• To review pediatric neurotransmitter disorders, focusing on diagnosis and management.
• To highlight the spectrum of these inherited neurometabolic conditions.
• To discuss therapeutic strategies, including neurotransmitter supplementation.

Main Methods:

• Review of inherited neurometabolic syndromes affecting neurotransmitter pathways.
• Classification of disorders based on diagnostic markers (CSF assay, serum phenylalanine).
• Analysis of clinical manifestations and treatment responses.

Main Results:

• Disorders vary in presentation, with some requiring cerebrospinal fluid (CSF) analysis for diagnosis.
• GTP cyclohydrolase deficiency shows a good response to therapy.
• Other deficiencies, like aromatic amino acid decarboxylase and tyrosine hydroxylase, present more severe phenotypes.
• Elevated serum phenylalanine indicates deficiencies in GTP cyclohydrolase, pterin-carbinolamine dehydratase, dihydropteridine reductase, and pyruvoyl-tetrahydropterin synthase.
• Pyruvoyl-tetrahydropterin synthase deficiency is common and heterogeneous, with diverse neurological symptoms.
• Monoamine degradation deficiencies cause cognitive, behavioral, and autonomic issues.

Conclusions:

• Effective management of pediatric neurotransmitter disorders relies on accurate diagnosis and timely intervention.
• Neurotransmitter supplementation and dopaminergic agonists are key therapeutic options.
• Specific treatments, like folinic acid for dihydropteridine reductase deficiency, can reverse certain manifestations.